Eli Lilly to supply 650,000 additional Covid doses to US Govt
Advertisement
New Delhi: Eli Lilly and Co said on Wednesday the U.S. government has purchased 650,000 additional doses of its Covid-19 antibody drug for $812.5 million.
The doses will be delivered through Jan. 31, with at least 350,000 delivered in December, the company said.
The drug has been authorized by the U.S. Food and Drug Administration for emergency use, and the government bought 300,000 doses in October.
The new purchase is part of a U.S. government deal to secure nearly 1 million doses of Lilly's bamlanivimab, a treatment similar to Regeneron Pharmaceuticals Inc's Covid-19 antibody therapy that U.S. President Donald Trump received in October during his illness.
The treatments belong to a class of drugs called monoclonal antibodies that are manufactured copies of antibodies created by the body to fight against an infection.
Lilly anticipates manufacturing up to one million doses of bamlanivimab by the end of 2020 for use around the world through early next year.
Read also: Eli Lilly arthritis drug baricitinib in combination with remdesivir gets USFDA okay to treat Covid
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.